Financial Results
for the Fiscal Year Ending January 31, 2022
SanBio Company Limited
(TSE Mothers: 4592)
March 11, 2022
1
Table of Contents
- Financial Results
- SB623 Approval in Japan and Sales Structure After Approval
- Toward Maximizing Corporate Value
- Q&A
2
Copyright（C） 2022 All Rights Reserved, SanBio Company Limited
1. Financial Results
3
Copyright（C） 2022 All Rights Reserved, SanBio Company Limited
Consolidated Income Statement
R&D expenses rose on increased spending related to manufacturing toward approval filing of
SB623 chronic TBI program in Japan.
FY2021.1 | FY2022.1 | (B)-(A) | FY2022.1 | ||||
Results (A) | Results (B) | Forecast | |||||
Million Yen | |||||||
Revenue | - | - | - | - | |||
R&D | 4,071 | 4,955 | 884 | 3,820 | |||
expenses | |||||||
Operating expenses | 5,801 | 6,618 | 817 | 5,786 | |||
Operating income | -5,801 | -6,618 | -817 | -5,786 | |||
Net income | -3,385 | -4,675 | -1,290 | -5,877 | |||
Yen/US$ exchange | 106.34 | 110.73 | - | 110.00 | |||
rate | |||||||
4
Copyright（C） 2022 All Rights Reserved, SanBio Company Limited
Consolidated Balance Sheet
Cash & cash equivalents and net assets declined. Began procuring funds in February 2022 to fortify
financial base in light of future business development.
As of January 31, | As of January 31, | (B)-(A) | |||
2021 (A) | 2022 (B) | ||||
Million yen | |||||
Cash & cash | 12,480 | 4,557 | -7,923 | ||
equivalents | |||||
Supplies | 444 | 467 | 23 | ||
Current assets | 13,131 | 5,351 | -7,780 | ||
Non-current assets | 211 | 159 | -52 | ||
Total assets | 13,343 | 5,510 | -7,833 | ||
Current liabilities | 2,469 | 1,461 | -1,008 | ||
Non-current liabilities | 2,525 | 2,012 | -513 | ||
Total liabilities | 4,994 | 3,473 | -1,521 | ||
Net assets | 8,349 | 2,037 | -6,312 | ||
Total liabilities and net | 13,343 | 5,510 | -7,833 | ||
assets | |||||
5
Copyright（C） 2022 All Rights Reserved, SanBio Company Limited
This is an excerpt of the original content. To continue reading it, access the original document here.